Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

Recruiting in Palo Alto (17 mi)

Overseen by Lisa Barroilhet, MD

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: University of Wisconsin, Madison

Stay on Your Current Meds

No Placebo Group

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

This study tests the hypothesis that IV iron sucrose infusions given to iron deficient ovarian cancer patients prior to debulking surgery can improve pre-operative iron stores and decrease transfusion of packed red blood cells in the peri-operative period. 21 participants at least 18 years of age with epithelial ovarian cancer of any stage requiring neoadjuvant chemotherapy and surgery will be enrolled. Participants will be on study for a period of up to 3 months.

Eligibility Criteria

Inclusion Criteria

Has a diagnosis of true or functional iron deficiency without anemia within 30 days of treatment on this protocol

Provide written informed consent.

Iron deficiency without anemia (normal Hgb >/= 11.6 g/dL but ferritin < 30 ng/mL)

Treatment Details

Interventions

• Iron Sucrose (Iron Supplement)

Participant Groups

Group I: IV Iron Sucrose Experimental Treatment 1 Intervention

Four intravenous iron sucrose infusions prior to debulking surgery administered as four 200mg infusions, given no less than 7 days apart over a 30 day +/- 7 day period

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

University of Wisconsin Carbone Cancer Center Madison, WI

Who Is Running the Clinical Trial?

University of Wisconsin, Madison Lead Sponsor

References